NewishT Cell Therapy for HCC With High Risk of Recurrence After Radical Resection
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This is a single-arm, open label, multi-center Phase 1 clinical study to evaluate the safety
and efficacy of autologous memory lymphocyte therapy (NewishT) in patients with
hepatocellular carcinoma at high risk of recurrence after radical resection.
Phase:
Phase 1
Details
Lead Sponsor:
Newish Technology (Beijing) Co., Ltd.
Collaborator:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences